Dozee vs Healx

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Dozee employs 50-200 people, while Healx has 1-50 employees.

Healx has raised more in total funding at $47M, compared to Dozee's $20M — a gap of $27M.

Dozee holds the higher Awaira Score at 60/100, compared to Healx's 55/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 5-point gap that reflects meaningful differences in scale or traction.

Dozee was founded by Mudit Dandwate in 2015. Healx was founded by Tim Guilliams in 2014. Visit each company's profile on Awaira for a full founder biography.

Dozee: Dozee builds a contactless remote patient monitoring system that uses a ballistocardiography sensor placed under a mattress to continuously track heart rate, respiratory rate, blood pressure trends, and sleep quality, transmitting data to an AI analysis platform that generates clinical-grade early warning scores for hospital staff. The system requires no wearables or patient cooperation, enabling continuous monitoring for elderly patients, post-surgical recovery, and ICU step-down units.\n\nThe company raised approximately $20M in Series B funding and has deployed its monitoring systems across hospitals in India and internationally, with evidence of measurable reductions in deterioration events and ICU transfers through early warning. Dozee's central monitoring dashboard allows nursing staff to oversee multiple patients simultaneously with automated deterioration alerts.\n\nContinuous patient monitoring outside of ICU settings is an underserved clinical problem globally, and particularly acute in India where nurse-to-patient ratios in general wards are often insufficient for manual vital sign monitoring. Dozee's contactless approach and AI early warning capability address both the clinical quality and resource efficiency dimensions of this challenge. Healx: Healx uses AI to identify and develop treatments for rare diseases, applying graph neural networks and multi-omics data analysis to repurpose existing approved drugs for new orphan disease indications. The Cambridge-based company focuses exclusively on rare diseases, where the small patient populations and limited existing literature make traditional drug discovery economically unviable without computational approaches that can extract signal from sparse data.\n\nThe company raised a $47 million Series B led by Balderton Capital and includes strategic investors from the rare disease patient advocacy community. Healx has assembled a pipeline of repurposing candidates for conditions including Fragile X syndrome, tuberous sclerosis complex, and other rare neurodevelopmental disorders, with several candidates advancing into clinical studies. The company partners with patient advocacy groups to access natural history data and patient registries that inform its disease models.\n\nHealx operates in a rare disease AI market that is less crowded than oncology-focused drug discovery AI but equally challenging due to regulatory complexity and small trial populations. The company competes with Healios, BenevolentAI, and specialist rare disease biotechs that are increasingly adopting computational methods. Its exclusive focus on rare diseases and its community partnerships represent a defensible niche that larger generalist AI drug discovery platforms have not prioritised.

Healx was founded first in 2014, giving it 1 year of additional market experience. Dozee was founded later in 2015. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Dozee has approximately 50-200 employees, while Healx has approximately 1-50. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Dozee and Healx are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.